Bevacizumab has shown promising results in reversing the VEGF-induced inhibition of differentiation of monocytes into DCs in vitro [131], as well as in restoring peripheral blood DC numbers in cancer patients and promoting their activation [127,130]. This evidence concerns the gene VEGFA and cancer.